Background {#Sec1}
==========

*Schistosoma* sp. and HIV are co-endemic globally and an estimated 6 million individuals are co-infected worldwide \[[@CR1], [@CR2]\]. *Schistosoma* sp. infection has been shown to increase susceptibility to HIV and to impact HIV/AIDS outcomes \[[@CR3]--[@CR8]\]. It has been hypothesized that schistosome-induced down-regulation of T helper (Th)-1 immune responses may permit increased viral replication, and that T regulatory cells may also play an important role in the observed interactions.

Availability of antiretroviral therapy (ART) is increasing, with 61% of adults infected with HIV being on antiretroviral treatment in sub-Saharan Africa \[[@CR9]\]. Yet very little is known about the impact of *Schistosoma* sp. infection on the effectiveness of ART. One study from Tanzania showed schistosome infection to be significantly associated with immunological failure and poorer CD4+ T-cells (CD4) count gain with ART \[[@CR10]\]. However that study did not investigate whether the immunological failure was associated with concomitant increase of viral load (virological failure). Results from human studies of schistosome infection and HIV-1 RNA viral loads are variable, with some showing lower and some showing higher viral replication during schistosome co-infection \[[@CR3], [@CR11]--[@CR18]\].

Our group has recently demonstrated that people with schistosome infections have higher HIV-1 viral load set-points shortly following HIV acquisition, yet that in chronic HIV-schistosome co-infection, viral loads are lower than in those with HIV infection alone \[[@CR19]\]. To our knowledge, no report exists on the virological response to ART in schistosome-infected individuals. Furthermore, controlling for duration of HIV-1 infection appears to be a critical factor to consider in studies of HIV-1 and schistosome co-infection, since HIV-1 viral load differs over the course of infection \[[@CR19], [@CR20]\].

In the current study, we aimed to assess the impact of HIV-1/*Schistosoma* sp. co-infections on viral load in HIV-1 infected people with immunological failure on ART, taking into account the duration of HIV-1 infection.

Methods {#Sec2}
=======

Study participants and enrollment {#Sec3}
---------------------------------

This study was conducted in HIV outpatient clinics at Bugando Medical Centre (BMC) and Sekou Toure Hospital in Mwanza. The participants were HIV-1 infected adults over 18 years of age, who had used first line ART for more than 6 months and were identified to have immunological failure by the World Health Organization (WHO) criteria. Patients on stavudine-containing regimens were excluded due to this drug's known association with treatment failure \[[@CR21], [@CR22]\]. Eligible patients provided urine and stool samples for schistosomiasis testing by microscopy as well as serum for quantitation of schistosome circulating anodic antigen (CAA). Plasma was also collected for viral load measurement. Additional information was extracted from the HIV clinic database and the patient's chart.

Laboratory methods {#Sec4}
------------------

Tests for schistosome infections were performed at the National Institute of Medical Research in Mwanza, Tanzania. Microscopic examinations were performed on 10 mL of urine (for *S. haematobium*) by the filtration technique and on stool (for *S. mansoni*) following the Kato Katz method. CAA testing was performed as previously described using a luminescent up-converting phosphor technology in combination with a lateral flow-based platform (UCP-LF) \[[@CR23], [@CR24]\]. A 30 pg/mL cutoff threshold was used. Schistosome infection was defined as having either a positive microscopy or CAA test.

Plasma viral load was quantified using the AmpliPrep/COBAS® TaqMan® HIV-1 Test (Roche Molecular Systems Inc., Pleasanton, California, USA) machine at the BMC clinical laboratory, with a lower limit of detection of 20 copies/mL. Virological failure was defined as a viral load above 1000 copies/mL.

Statistical analysis {#Sec5}
--------------------

We estimated that we needed to enroll 190 patients to provide 80% power to detect the primary outcome, a predicted prevalence of virological treatment failure of 45% in those with schistosome infection compared to 25% in those without schistosomes, assuming that 30% of the study population would be infected with schistosomes \[[@CR10]\]. Data was double entered, verified and cleaned using Microsoft Excel 2013 and analysis was performed using STATA version 13. Chi-square tests and t-tests were used to compare presence of demographic and clinical factors in those with versus without schistosome infection. Univariable and multivariable linear regressions were used to determine factors associated with log~10~ of the viral load, including schistosome infection. All variables significantly associated with the outcome in the univariable analysis were included in the stepwise multivariable analysis. We pre-specified that we would include schistosome status and duration of HIV-1 infection in the model.

We calculated the time delay between HIV infection and start of ART using the normal CD4 decay per calendar year in drug naïve individuals as previously described \[[@CR19]\], assuming that the upper reference values of CD4 counts in healthy Tanzanians are 1278.9 cells/μL for men and 1406. 11 cells/μL for women \[[@CR25]\]. In addition, we used the overall CD4 decay per calendar year of 34.5 cells/ μL per year that had been reported from Rakai, Uganda, which has a similar HIV-1 clade composition to Mwanza, Tanzania \[[@CR26]--[@CR29]\].

We modeled decay by the square-root function \[[@CR28]\], which meant we subtracted 5.87 cells^0.5^/μL^0.5^ from 35.76 cells^0.5^/μL^0.5^ for men and 37.51 cells^0.5^/μL^0.5^ for women per calendar year until the square root of CD4 count found at time of start of ART was reached. The time period for this to happen was considered to be the estimated period between HIV-1 acquisition and start of ART. The time between start of ART and date of viral load testing was then added to this variable to obtain the total duration of HIV-1 infection. This led to an estimated median time from seroconversion to ART initiation of 4.4\[3. 11--5.1\] years, which is similar to what was found using HIV surveillance data \[Colombe et al., manuscript in revision\].

Definitions {#Sec6}
-----------

Immunological failure was defined as either a confirmed 50% drop from peak CD4 count (if known) during current treatment or as a CD4 count equal to or below baseline after 6-months of ART, or as a CD4 count below 100cells/mm3 after 1 year of ART as per WHO guidelines \[[@CR30]\]. Poor ART adherence was defined as missing 3 doses on 2 or more days of ART within the last 3 months according to Tanzanian national guidelines \[[@CR31]\]. This measure of adherence is routinely recorded at every monthly visit by nurses and doctors at the clinic \[[@CR31]\].

Results {#Sec7}
=======

From August to December 2014, we screened 237 outpatients who were diagnosed with immunological treatment failure while using first-line ART. Of these, 31 were using a stavudine-containing regimen, 10 had been on ART for less than 6 months, 6 did not want to participate in the study, and viral load testing failed on 5 patients. Thus we enrolled and analyzed data from a total of 188 patients.

The median age was 41.0 \[36.0--46.5\] years and 116 (61.7%) of participants were female. The majority of participants resided in urban areas (152, 80.9%), were employed and selling food (89, 47. 3%), and had completed only primary education (118, 62. 11%). 63/87 (72%) of anemic patients were female (*p* = 0.005). 79/188 (42.0%) of patients had \> 1000 viral copies/mL. Among those with viral loads \< 1000 copies/mL, 94 (86.2%) were virologically suppressed with viral loads \< 20 copies/mL. 85/173 (49.1%) had either a microscopy positive test or a positive CAA test for *Schistosoma* sp. (Table [1](#Tab1){ref-type="table"}). More specifically, 19/170 (11.18%) had a stool microscopy positive test, no one had a urine microscopy positive test and 82/188 (43.62%) had a positive CAA test. Sixteen people were positive both by CAA and microscopy test.Table 1Demographic characteristics of 188 HIV-1 outpatients with immunological treatment failure on ARTVariableViral load \> 1000 copies/mL\
N (%) or Median \[IQR\]\
*N* = 79Viral load \< = 1000 copies/mL\
N (%) or Median \[IQR\]\
*N* = 109*p*-valueFemale53/79 (67.1%)63/109 (57.8%)0.20Age in years40 \[34--46\]42 \[37--48\]0.034Level of education0.44 Informal47/79 (59.5%)71/109 (65.1%) Any primary schooling21/79 (26.6%)23/109 (21.1%) Any secondary schooling3/79 (3.8%)1/109 (0.9%) Any university8/79 (10.1%)14/109 (12.8%)Time on ART0.25 6 m--1y2/79 (2.5%)1/109 (0.9%) 1--2y6/79 (7.6%)18/109 (16.5%) 2--3y14/79 (17.7%)16/109 (14.7%) \>3y57/79 (72.2%)74/109 (67.9%)ART Regimen0.77 AZT/3TC/NVP35/79 (44.3%)49/109 (45.0%) AZT/3TC/EFV10/79 (12.7%)19/109 (17.4%) TDF/3TC/EFV22/79 (27.8%)28/109 (25.7%) TDF/3TC/EFV12/79 (15.2%)13/109 (11.9%)History of change ART Regimen34/79 (43.0%)40/109 (36.7%)0.38Peak CD4 (cells/μL)358 \[202--506\]450 \[317--630\]0.0027Current CD4 (cells/μL)104 \[47--179\]192 \[125--239\]\< 0.001History of stopping ART19/79 (24.1%)16/109 (14.7%)0.10Use of herbal/alternative medicine32/79 (40.5%)54/109 (49.5%)0.22Other comorbidities0.38 None73/79 (92.4%)94/109 (86.2%) Hypertension4/79 (5.1%)8/109 (7.3%) Others (Diabetes, heart failure, asthma etc.)2/79 (2.5%)7/109 (6.4%)Body mass index in kg/m^2^21.5 \[18.9--25.4\]22 \[19.9--24.0\]0.65Anemia (Hemoglobin\< 12 g/dl)50/79 (6.3%)37/109 (33.9%)\< 0.001Schistosome positivity36/71 (50.7%)49/102 (48.0%)0.73Ln of CAA (pg/ml)3.05 \[2.1--5.2\]2.8 \[2.0--6.1\]0.65Years infected with HIV-18.9 \[6.6--11.1\]9.9 \[7.7--11.4\]0.068

After univariable analysis, female sex, lower peak CD4 counts, lower current CD4 counts, anemia, and shorter time infected with HIV-1 were all significantly associated with higher log~10~ of viral load. Schistosome infection was not associated with log~10~ of viral load.

After multivariable analysis, the best fit model included sex and current CD4 counts. We kept duration of HIV-1 infection in the model. Results of both the univariable and multivariable analyses are presented in Table [2](#Tab2){ref-type="table"}. Neither schistosome infection nor duration of HIV-1 infection was associated with log~10~ of viral load. The interaction between sex and schistosome status and its impact on log~10~ of viral load was not statistically significant.Table 2Results of univariable and multivariable analyses of factors associated with log~10~ of viral loadVariableUnivariable analysisMultivariable analysisSlope coefficient \[95%CI\]*p*-valueSlope coefficient \[95%CI\]*p*-valueFemale0.6 \[0.07;1.2\]0.0290.6 \[0.05;1.2\]0.034Age (as a continuous variable)− 0.02 \[− 0.05;0.006\]0.11Level of education InformalRef Any primary schooling0.2 \[− 0.5;0.9\]0.56 Any secondary schooling−0.08 \[− 1.8;1.6\]0.92 Any university0.03 \[− 0.98;1.04\]0.95Time on ART 6 m-1yRef 1--2y−1.6 \[−4.0;0.8\]0.20 2--3y−1.0 \[− 3.4;1.4\]0.40 \>3y− 0.7 \[− 3.0;1.6\]0.53History of change ART Regimen0.2 \[− 0.4;0.8\]0.42Highest/Peak CD4 (cells/μL) \< 200Ref 200--500−0.8 \[− 1.6;-0.05\]0.037 500--1000− 1.1 \[− 1.9;-0.3\]0.011 \> 1000−3.0 \[− 6.2;0.2\]0.068Current CD4 (cells/μL) \< 100RefRef 100--200− 0.5 \[− 1.2;0.08\]0.090−0.5 \[− 1.1;0.2\]0.15 200--300−1.4 \[−2.2;-0.7\]\< 0.001-1.3 \[− 2.1;-0.5\]0.001 \> 300-2.8 \[−5.0;-0.6\]0.014-3.0 \[− 5.2;-0.8\]0.007History of stopping ART−0.05 \[− 0.7;0.6\]0.89Use of herbal/alternative medicine−0.1 \[− 0.7;0.4\]0.61Other comorbidities NoneRef Hypertension−0.7 \[− 1.9;0.6\]0.30 Others (Diabetes, heart failure, asthma etc.)−0.7 \[− 2.2;0.8\]0.34Anemia0.8 \[0.3--1.4\]0.005Schistosome positivity0.15 \[− 0.5;0.8\]0.630.1 \[−0.4;0.7\]0.68Ln of CAA (in ln pg/mL)0.03 \[−0.04;0.1\]0.42Years infected with HIV-10.1 \[0.01;0.2\]0.0270.06 \[−0.06;0.2\]0.32

When looking at whether the median log~10~ of viral load between schistosome infected and non-infected patients changed over time, we found no significant differences (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Difference in log~10~ of viral load by schistosome status and time infected with HIV-1. Figure shows no difference in median of log~10~ of viral load between schistosome infected and uninfected patients with immunological failure on ART across time infected with HIV-1

Discussion {#Sec8}
==========

We found no association between schistosome infection and viral loads among patients with immunological failure, including after adjustment for time infected with HIV-1. This suggests that observed effects of schistosome infection on HIV-1 viral load occur in the absence of ART and that, once ART commences, effective ART is the dominant driver of viral load. In addition, our finding suggests that the increased immunological failure found by Efraim et al. might be due to an effect of *Schistosoma* sp*.* on CD4 counts, but not on viral loads, in people on ART \[[@CR10]\].

Our findings, adjusting for duration of HIV-1 infection, differ from those in ART-naïve patients in the same clinic, where schistosome-infection was associated with lower viral loads after adjustment for duration of HIV infection \[[@CR19]\]. It is likely that the effect of ART, which typically decreases the viral load by several log~10~ fold copies/mL, is so strong that it would mask any effect of schistosome infection on viral load, which we estimated in our prior study to cause a difference of 0.7 log10 copies/mL in ART-naïve patients. Viral load dynamics of patients on ART appear to be vastly different from those of ART naïve patients, as suggested by the fact that baseline viral loads do not predict viral load rebounds on ART in previously ART-naïve patients \[[@CR32]\].

Expectedly, higher peak and current CD4 counts were associated with lower viral load. This finding is consistent with several other studies in sub-Saharan Africa \[[@CR33], [@CR34]\]. Similarly the association between anemia and higher viral load has been shown before \[[@CR35]\]. The significant association of female sex with higher viral load as observed in our study contradicted what is usually reported \[[@CR33], [@CR36], [@CR37]\]. This might be due to the fact that women were significantly more likely to have anemia, which itself is associated with higher viral load and became insignificant when included in the multivariable analysis.

These results need to be considered in light of some limitations. The study included only people with immunological failure, implying that our cohort has overall low CD4 count and thus high viral loads. In addition, as immunological failure is also associated with specific host and viral genetics \[[@CR38], [@CR39]\], our overall findings may not directly apply to each individual patient on ART. Finally the sample size was calculated for a statistical analysis based on a binary outcome rather than a continuous one. By using viral load as a continuous variable, we lose some power. Nonetheless, the conclusions when using a binary outcome remain the same (Unadjusted Odds Ratio = 1.11\[0.61--2.04\], *p* = 0.73; Odds Ratio adjusted for CD4 counts and anemia = 0.99\[0.50--1.95\], *p* = 0.98).

Conclusions {#Sec9}
===========

In conclusion, our study suggests that schistosome infection does not impact viral load in HIV-1 infected patients immunologically failing on ART, likely due to the major effects of ART on viral load once ART is initiated.
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